For the twelve months ended Sep 30, 2026, iRadimed Corporation reported $89.34M of revenue and $23.98M of net income.
IRMD revenue was $24.20M in fiscal Q3 2026 (ended Sep 30, 2026), up 14.2% from a year earlier and up 18.3% from the prior quarter. For the full fiscal 2025 it was $83.81M, up 14.4% from fiscal 2024. Compound annual growth was +21.5% over 5 years and +10.2% over 10 years. It rose in 8 of the last 10 fiscal years. Fiscal 2025 is the highest of the 13 fiscal years on file.
IRMD net income was $6.51M in fiscal Q3 2026 (ended Sep 30, 2026), up 16.7% from a year earlier and up 24.7% from the prior quarter. For the full fiscal 2025 it was $22.48M, up 16.9% from fiscal 2024. Compound annual growth was +75.0% over 5 years and +11.6% over 10 years. It rose in 7 of the last 10 fiscal years. Fiscal 2025 is the highest of the 13 fiscal years on file.
IRMD diluted EPS was $0.51 in fiscal Q3 2026 (ended Sep 30, 2026), up 18.6% from a year earlier and up 24.4% from the prior quarter. For the full fiscal 2025 it was $1.75, up 16.7% from fiscal 2024. Compound annual growth was +73.9% over 5 years and +11.3% over 10 years.
IRMD free cash flow was $6.87M in fiscal Q3 2026 (ended Sep 30, 2026), up 17.4% from a year earlier and up 19.3% from the prior quarter. For the full fiscal 2025 it was $17.18M, down 2.5% from fiscal 2024. Compound annual growth was +26.2% over 5 years and +8.9% over 10 years. It rose in 5 of the last 10 fiscal years.
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $83.81M | $73.24M | $65.56M | $53.30M | $41.81M | $31.72M | $38.52M | $30.44M | $23.08M | $32.50M |
| Cost of revenue | $19.49M | $16.89M | $15.40M | $12.02M | $9.76M | $8.14M | $8.82M | $7.21M | $5.57M | $6.15M |
| Gross profit | $64.32M | $56.35M | $50.16M | $41.28M | $32.05M | $23.57M | $29.70M | $23.23M | $17.51M | $26.34M |
| Research and development | $2.98M | $2.83M | $2.86M | $2.28M | $1.91M | $1.90M | $1.43M | $1.52M | $1.72M | $1.35M |
| Selling, general and admin | $17.78M | $15.94M | $15.12M | $10.70M | $9.77M | $12.27M | $10.45M | $8.71M | $9.00M | $8.80M |
| Operating income | $26.15M | $21.96M | $20.04M | $15.63M | $9.82M | -$756.1K | $8.65M | $6.00M | $1.29M | $10.92M |
| Pre-tax income | $28.36M | $24.27M | $21.74M | $16.18M | $9.84M | -$616.9K | $9.04M | $6.20M | $1.40M | $10.95M |
| Income tax | $5.88M | $5.04M | $4.55M | $3.35M | $510.8K | -$1.99M | -$587.6K | -$106.1K | $896.6K | $3.74M |
| Net income | $22.48M | $19.23M | $17.19M | $12.83M | $9.33M | $1.37M | $9.63M | $6.30M | $499.8K | $7.21M |
| EPS, basic | $1.77 | $1.52 | $1.36 | $1.02 | $0.76 | $0.11 | $0.85 | $0.59 | $0.05 | $0.67 |
| EPS, diluted | $1.75 | $1.50 | $1.35 | $1.02 | $0.74 | $0.11 | $0.78 | $0.52 | $0.04 | $0.60 |
| Diluted shares | 12.9M | 12.8M | 12.7M | 12.6M | 12.6M | 12.4M | 12.3M | 12.1M | 11.7M | 12.0M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $51.16M | $52.23M | $49.76M | $57.96M | $62.00M | $50.07M | $43.48M | $28.03M | $18.21M | $17.71M |
| Receivables | $13.67M | $10.56M | $12.22M | $13.27M | $5.14M | $4.57M | $7.29M | $4.21M | $3.78M | $3.78M |
| Inventory | $11.62M | $10.40M | $12.82M | $5.37M | $4.30M | $3.93M | $3.64M | $4.06M | $4.21M | $3.89M |
| Current assets | $81.20M | $75.24M | $76.00M | $77.49M | $76.24M | $63.74M | $58.96M | $44.54M | $35.11M | $33.86M |
| Total assets | $108.78M | $98.33M | $92.16M | $85.51M | $82.88M | $71.07M | $66.73M | $48.44M | $39.01M | $37.19M |
| Current liabilities | $10.18M | $8.51M | $16.33M | $8.55M | $6.82M | $4.92M | $5.86M | $4.69M | $4.08M | $3.66M |
| Total liabilities | $14.16M | $11.51M | $20.74M | $11.84M | $10.71M | $9.68M | $11.20M | $6.50M | $6.08M | $5.31M |
| Shareholders' equity | $94.62M | $86.82M | $71.42M | $73.67M | $72.17M | $61.38M | $55.52M | $41.95M | $32.93M | $31.89M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $24.95M | $25.62M | $13.47M | $10.04M | $11.26M | $5.82M | $10.23M | $7.38M | $3.42M | $9.41M |
| Capital expenditures | $7.76M | $8.01M | $7.44M | $823.0K | $482.3K | $443.0K | $368.3K | $228.3K | $775.6K | $780.8K |
| Free cash flow | $17.18M | $17.62M | $6.02M | $9.22M | $10.78M | $5.37M | $9.86M | $7.15M | $2.64M | $8.63M |
| Investing cash flow | -$8.42M | -$8.82M | -$8.01M | -$1.37M | $648.2K | $247.0K | $3.20M | $1.52M | -$1.02M | -$1.94M |
| Financing cash flow | -$17.60M | -$14.34M | -$13.66M | -$12.71M | $24.4K | $522.5K | $2.02M | $929.9K | -$1.90M | -$9.12M |
| Dividends paid | $15.04M | $13.68M | $13.22M | $12.56M | - | - | - | - | - | - |
| Share repurchases | - | - | - | - | - | - | - | - | $1.82M | $9.97M |
| Stock-based compensation | $2.92M | $2.52M | $2.19M | $1.39M | $1.46M | $3.96M | $1.85M | $1.76M | $2.45M | $1.84M |
| Depreciation and amortization | $1.17M | $818.0K | $765.2K | $670.7K | $1.41M | $1.34M | $1.24M | $1.11M | $1.31M | $955.8K |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | 14.4% | 11.7% | 23.0% | 27.5% | 31.8% | -17.7% | 26.5% | 31.9% | -29.0% | 2.9% |
| Net income growth, YoY | 16.9% | 11.9% | 34.0% | 37.6% | 581.2% | -85.8% | 52.8% | 1161.3% | -93.1% | -4.2% |
| EPS growth, YoY | 16.7% | 11.1% | 32.4% | 37.8% | 572.7% | -85.9% | 50.0% | 1200.0% | -93.3% | 0.0% |
| Gross margin | 76.7% | 76.9% | 76.5% | 77.4% | 76.6% | 74.3% | 77.1% | 76.3% | 75.9% | 81.1% |
| Operating margin | 31.2% | 30.0% | 30.6% | 29.3% | 23.5% | -2.4% | 22.5% | 19.7% | 5.6% | 33.6% |
| Net margin | 26.8% | 26.3% | 26.2% | 24.1% | 22.3% | 4.3% | 25.0% | 20.7% | 2.2% | 22.2% |
| Free cash flow margin | 20.5% | 24.1% | 9.2% | 17.3% | 25.8% | 16.9% | 25.6% | 23.5% | 11.4% | 26.5% |
| Return on equity | 23.8% | 22.2% | 24.1% | 17.4% | 12.9% | 2.2% | 17.3% | 15.0% | 1.5% | 22.6% |
| Return on assets | 20.7% | 19.6% | 18.7% | 15.0% | 11.3% | 1.9% | 14.4% | 13.0% | 1.3% | 19.4% |
| Current ratio | 7.98 | 8.84 | 4.65 | 9.06 | 11.18 | 12.96 | 10.06 | 9.50 | 8.61 | 9.25 |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $24.20M | $20.47M | $21.98M | $22.69M | $21.20M | $20.41M | $19.51M | $19.39M | $18.33M | $17.93M | $17.60M | $17.45M |
| Cost of revenue | $5.75M | $5.31M | $5.17M | $5.66M | $4.71M | $4.45M | $4.67M | $4.63M | $4.13M | $3.92M | $4.21M | $4.04M |
| Gross profit | $18.46M | $15.16M | $16.81M | $17.03M | $16.49M | $15.96M | $14.84M | $14.76M | $14.19M | $14.01M | $13.39M | $13.41M |
| Research and development | $875.0K | $657.0K | $956.0K | $799.0K | $674.0K | $877.0K | $624.0K | $570.4K | $639.5K | $801.1K | $821.0K | $650.4K |
| Selling, general and admin | $4.53M | $3.87M | $4.57M | $4.54M | $4.36M | $4.28M | $4.61M | $3.87M | $3.97M | $4.10M | $3.99M | $4.27M |
| Operating income | $8.14M | $6.39M | $7.24M | $7.09M | $6.83M | $6.79M | $5.43M | $5.80M | $5.79M | $5.63M | $4.75M | $5.16M |
| Pre-tax income | $8.67M | $6.89M | $7.77M | $7.79M | $7.30M | $7.33M | $5.95M | $6.34M | $6.42M | $6.27M | $5.24M | $5.68M |
| Income tax | $2.16M | $1.67M | $1.95M | $1.35M | $1.72M | $1.55M | $1.26M | $1.20M | $1.37M | $1.37M | $1.11M | $1.14M |
| Net income | $6.51M | $5.22M | $5.82M | $6.44M | $5.58M | $5.77M | $4.69M | $5.15M | $5.05M | $4.90M | $4.14M | $4.54M |
| EPS, basic | $0.51 | $0.41 | $0.46 | $0.51 | $0.44 | $0.45 | $0.37 | $0.40 | $0.40 | $0.39 | $0.33 | $0.36 |
| EPS, diluted | $0.51 | $0.41 | $0.45 | $0.50 | $0.43 | $0.45 | $0.37 | $0.40 | $0.40 | $0.38 | $0.32 | $0.35 |
| Diluted shares | 12.9M | 12.9M | 12.9M | - | 12.9M | 12.8M | 12.8M | - | 12.8M | 12.8M | 12.7M | - |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $63.29M | $59.08M | $56.37M | $51.16M | $56.53M | $53.00M | $50.33M | $52.23M | $51.72M | $48.54M | $45.13M | $49.76M |
| Receivables | $13.67M | $13.19M | $13.41M | $13.67M | $13.86M | $10.92M | $12.71M | $10.56M | $10.36M | $11.95M | $13.03M | $12.22M |
| Inventory | $13.49M | $12.26M | $11.88M | $11.62M | $11.73M | $11.20M | $10.56M | $10.40M | $11.25M | $12.07M | $12.70M | $12.82M |
| Current assets | $92.80M | $86.72M | $86.42M | $81.20M | $84.92M | $77.37M | $75.14M | $75.24M | $74.29M | $73.58M | $71.89M | $76.00M |
| Total assets | $121.07M | $114.97M | $114.39M | $108.78M | $114.72M | $106.45M | $101.73M | $98.33M | $94.25M | $89.95M | $88.01M | $92.16M |
| Current liabilities | $10.32M | $9.16M | $12.12M | $10.18M | $12.80M | $8.81M | $8.47M | $8.51M | $8.06M | $7.46M | $7.62M | $16.33M |
| Total liabilities | $14.62M | $13.23M | $15.88M | $14.16M | $16.37M | $12.15M | $11.68M | $11.51M | $10.81M | $10.28M | $11.89M | $20.74M |
| Shareholders' equity | $106.45M | $101.75M | $98.51M | $94.62M | $98.35M | $94.30M | $90.06M | $86.82M | $83.43M | $79.67M | $76.12M | $71.42M |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $7.00M | $5.94M | $8.29M | $5.92M | $6.99M | $7.75M | $4.29M | $5.99M | $9.12M | $6.64M | $3.88M | $3.91M |
| Capital expenditures | $130.0K | $185.0K | $403.0K | $294.0K | $1.14M | $2.64M | $3.70M | $2.79M | $3.81M | $1.13M | $270.6K | $531.9K |
| Free cash flow | $6.87M | $5.75M | $7.89M | $5.63M | $5.85M | $5.11M | $595.0K | $3.20M | $5.31M | $5.50M | $3.61M | $3.38M |
| Investing cash flow | -$212.0K | -$443.0K | -$469.0K | -$416.0K | -$1.26M | -$2.82M | -$3.92M | -$3.06M | -$4.01M | -$1.27M | -$478.8K | -$632.8K |
| Financing cash flow | -$2.58M | -$2.79M | -$2.61M | -$10.87M | -$2.19M | -$2.26M | -$2.28M | -$2.42M | -$1.92M | -$1.96M | -$8.04M | -$262.6K |
| Dividends paid | $2.56M | $2.56M | $2.56M | $8.55M | $2.16M | $2.16M | $2.16M | $1.90M | $1.90M | $1.90M | $7.98M | $0 |
| Stock-based compensation | $777.0K | $807.0K | $684.0K | $696.0K | $666.0K | $731.0K | $826.0K | $656.3K | $630.0K | $609.1K | $628.6K | $551.1K |
| Depreciation and amortization | $412.0K | $410.0K | $455.0K | $381.0K | $383.0K | $208.0K | $194.0K | $195.2K | $197.6K | $199.1K | $226.1K | $205.4K |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | 14.2% | 0.3% | 12.6% | 17.0% | 15.7% | 13.8% | 10.9% | 11.1% | 11.0% | 11.1% | 13.7% | 17.4% |
| Net income growth, YoY | 16.7% | -9.6% | 24.1% | 25.2% | 10.4% | 17.8% | 13.3% | 13.4% | -0.3% | 17.3% | 21.4% | 23.6% |
| EPS growth, YoY | 18.6% | -8.9% | 21.6% | 25.0% | 7.5% | 18.4% | 15.6% | 14.3% | 0.0% | 15.2% | 18.5% | 20.7% |
| Gross margin | 76.3% | 74.1% | 76.5% | 75.1% | 77.8% | 78.2% | 76.1% | 76.1% | 77.4% | 78.1% | 76.1% | 76.9% |
| Operating margin | 33.6% | 31.2% | 32.9% | 31.3% | 32.2% | 33.3% | 27.8% | 29.9% | 31.6% | 31.4% | 27.0% | 29.6% |
| Net margin | 26.9% | 25.5% | 26.5% | 28.4% | 26.3% | 28.3% | 24.0% | 26.5% | 27.6% | 27.3% | 23.5% | 26.0% |
| Free cash flow margin | 28.4% | 28.1% | 35.9% | 24.8% | 27.6% | 25.0% | 3.0% | 16.5% | 29.0% | 30.7% | 20.5% | 19.4% |
| Current ratio | 8.99 | 9.46 | 7.13 | 7.98 | 6.64 | 8.78 | 8.87 | 8.84 | 9.21 | 9.87 | 9.44 | 4.65 |
Source: XBRL data iRadimed Corporation files with the SEC, latest filing dated Oct 30, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| IRMD | $89.34M | +11.0% | $23.98M | 26.8% | $1.11B |
| SYK | $26.30B | +7.9% | $3.62B | 13.8% | $124.00B |
| MMM | $25.25B | +1.7% | $3.54B | 14.0% | $97.47B |
| BSX | $21.07B | +8.9% | $3.50B | 16.6% | $63.81B |
| BDX | $23.25B | +17.4% | $941.00M | 4.0% | $58.63B |
| MDLN | $30.68B | - | $683.00M | 2.2% | $53.55B |
| RMD | $5.73B | +9.0% | $1.59B | 27.8% | $33.16B |
| DXCM | $5.10B | +13.0% | $991.00M | 19.4% | $30.24B |
| WST | $3.40B | +12.6% | $638.90M | 18.8% | $28.78B |